0000899243-20-033730.txt : 20201214 0000899243-20-033730.hdr.sgml : 20201214 20201214160509 ACCESSION NUMBER: 0000899243-20-033730 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201208 FILED AS OF DATE: 20201214 DATE AS OF CHANGE: 20201214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee June CENTRAL INDEX KEY: 0001696493 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36620 FILM NUMBER: 201386205 MAIL ADDRESS: STREET 1: C/O MYOKARDIA, INC. STREET 2: 333 ALLERTON AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Novus Therapeutics, Inc. CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-238-8090 MAIL ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc DATE OF NAME CHANGE: 20070622 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-12-08 0 0001404281 Novus Therapeutics, Inc. NVUS 0001696493 Lee June C/O NOVUS THERAPEUTICS, INC. 19900 MACARTHUR BLVD., SUITE 550 IRVINE CA 92612 1 0 0 0 Stock Option (Right to Buy) 19.74 2030-12-08 Common Stock 40000 D This option represents a right to purchase up to 40,000 shares of Common Stock, which option vests with respect to 20,000 shares on December 8, 2021 and with respect to 20,000 shares on December 8, 2022. Ex. 24 - Power of Attorney No securities are beneficially owned. /s/ Ryan A. Murr, as attorney-in-fact for June Lee 2020-12-14 EX-24 2 attachment1.htm EX-24 DOCUMENT

                               POWER OF ATTORNEY

     Know all by these presents, that the undersigned hereby constitutes and
appoints Jon Kuwahara and Ryan A. Murr, with full power of substitution, the
undersigned's true and lawful attorney-in-fact to:

     (1)   prepare, execute in the undersigned's name and on the undersigned's
behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a
Form ID, including amendments thereto, and any other documents necessary or
appropriate to  obtain codes, passwords and passphrases enabling the undersigned
to make electronic filings with the SEC of reports required by the Securities
Exchange Act of 1934 or any rule or regulation of the SEC;

     (2)   execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of Novus Therapeutics, Inc. (the
"Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities
Exchange Act of 1934 and the rules thereunder;

     (3)   do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and  execute any such Form 3, 4,
or 5, complete and execute any amendment or amendments thereto, and timely file
such form with  the SEC and any securities exchange or similar authority; and

     (4)   take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

     The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned also ratifies hereby any action previously taken by
each attorney-in-fact that would have been authorized by this power of attorney
if it has been in effect at the time such action was taken. The undersigned
acknowledges that the foregoing attorney-in-fact, in serving in such capacity at
the request of the undersigned, is not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934, as amended.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorney-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 11th day of December 2020.


                         /s/ June Lee
                         ----------------------------
                         June Lee, M.D.